Stocktoria
LEXICON PHARMACEUTICALS, INC. LXRX
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2000-04-07
LEXICON PHARMACEUTICALS, INC. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $49.8M | $31.1M | $1.2M | $139,000 | $298,000 | $24.0M | $322.1M | $63.2M | $91.7M | $79.3M |
| R&D expense | $61.1M | $84.5M | $58.9M | $52.8M | $55.0M | $153.6M | $91.9M | $100.2M | $152.2M | $164.0M |
| SG&A expense | $37.3M | $143.1M | $114.0M | $48.1M | $32.3M | — | — | — | — | — |
| Operating income | -$48.9M | -$197.1M | -$171.8M | -$100.8M | -$87.1M | -$47.8M | $141.4M | -$103.3M | -$130.6M | -$127.2M |
| Interest expense | — | — | — | $2.8M | $802,000 | $14.5M | $20.7M | $20.8M | $7.0M | $6.6M |
| Income tax | — | $0 | $0 | $0 | $0 | — | — | — | — | $0 |
| Net income | -$50.3M | -$200.4M | -$177.1M | -$101.9M | -$87.8M | -$58.6M | $130.1M | -$120.5M | -$123.0M | -$131.4M |
| EPS (diluted) | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 | $-0.53 | $1.16 | $-1.14 | $-1.17 | — |
| Operating cash flow | -$67.9M | -$178.8M | -$161.9M | -$88.9M | -$87.0M | -$143.0M | $113.8M | -$148.6M | -$185.4M | -$175.6M |
| Free cash flow | -$67.9M | -$179.8M | -$162.4M | -$90.2M | -$88.2M | -$143.1M | $113.7M | -$148.7M | -$185.6M | -$175.9M |
| Cash & equivalents | $34.3M | $66.7M | $22.5M | $46.3M | $64.1M | $126.3M | $36.1M | $80.4M | $61.7M | $46.6M |
| Inventory | $281,000 | $231,000 | $381,000 | $0 | — | $0 | $4.2M | $4.7M | $1.9M | $0 |
| Total assets | $185.0M | $298.4M | $229.4M | $194.3M | $136.9M | $203.8M | $417.7M | $284.1M | $436.5M | $475.6M |
| Total liabilities | $77.4M | $152.5M | $136.3M | $77.2M | $23.3M | $47.4M | $300.6M | $310.5M | $368.3M | $318.2M |
| Shareholders' equity | $107.5M | $145.9M | $93.1M | $117.1M | $113.6M | $156.4M | $117.1M | -$26.4M | $68.3M | $167.5M |
Growth · year-over-year · Revenue CAGR -5%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +60.2% | +2481.5% | +766.2% | -53.4% | -98.8% | -92.5% | +409.5% | -31.1% | +15.7% | -39.0% |
| Net income growth | — | — | — | — | — | -145.0% | — | — | — | — |
| EPS growth | — | — | — | — | — | -145.7% | — | — | — | — |
| Free cash flow growth | — | — | — | — | — | -225.8% | — | — | — | -195.6% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.